

AssayMax™ Human Factor VII ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 12 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human Factor VII (Factor 7) ELISA Kit (High Sensitivity)

Catalog No. EF2007-7

Sample insert for reference use only
WHO Standard Calibrated Positive Control Included

Introduction

Factor VII (FVII) is a vitamin K-dependent plasma glycoprotein that is synthesized in the liver and circulates in blood as a single-chain inactive zymogen with a molecular mass of 50 kDa (1). Upon tissue damage and vascular injury, the cell surface receptor and cofactor tissue factor binds and allosterically activates factor VII to its active form, factor VIIa. The tissue factor/factor VIIa complex catalyzes the conversion of both factor IX to factor IXa and factor X to factor Xa to initiate coagulation via the extrinsic pathway (2-3). Very low levels of factor VII are associated with severe coagulation disorders (4). Elevated plasma levels of factor VII coagulant activity constitute an independent risk factor for fatal outcomes of coronary heart disease in middle-aged men (5).

Principle of the Assay

The AssayMax™ Human Factor VII ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of factor VII and factor VIIa in human plasma and serum samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures total human factor VII in approximately 4 hours. A polyclonal antibody specific for human factor VII has been pre-coated onto a 96-well microplate with removable strips. Factor VII in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human factor VII, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Factor VII Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human factor VII.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Factor VII Standard: Human factor VII in a buffered protein base, calibrated against WHO 4th International Standard (288 ng, lyophilized).
- Biotinylated Human Factor VII Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human factor VII (120 µl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- **Stop Solution (1x):** A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).
- **Positive Control:** 1 vial, lyophilized. See insert CEF20071.

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate
 as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and
 collect plasma. A 160-fold sample dilution is suggested into MIX Diluent;
 however, user should determine optimal dilution factor depending on
 application needs. The undiluted samples can be stored at -20°C or
 below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or
 Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 160-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater					
	(for reference only; please follow the insert for specific dilution suggested)					
	100x		10000x			
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.			
	1000x		100000x			
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution			
	Assuming the needed volume is less than or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 μl.			

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Factor VII Standard: Reconstitute the Human Factor VII Standard (288 ng, 576 mIU) with 3.2 ml of MIX Diluent to generate a 90 ng/ml (180 mIU/ml) standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (90 ng/ml) 2-fold with equal volume of MIX Diluent to produce 45, 22.5, 11.25, 5.625, 2.813, 1.406, and 0.703 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Any remaining stock solution should be stored at -20°C and used within 30 days. Avoid repeated freeze-thaw cycles.

Standard Point	Dilution	[FVII] (ng/ml)	[FVII] (mIU/ml)
P1	1 part Standard + 1 part MIX Diluent	45	90
P2	1 part P1 + 1 part MIX Diluent	22.5	45
Р3	1 part P2 + 1 part MIX Diluent	11.25	22.5
P4	1 part P3 + 1 part MIX Diluent	5.625	11.25
P5	1 part P4 + 1 part MIX Diluent	2.813	5.625
P6	1 part P5 + 1 part MIX Diluent	1.406	2.813
P7	1 part P6 + 1 part MIX Diluent	0.703	1.406
P8	MIX Diluent	0.0	0.0

- Biotinylated Human Factor VII Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with MIX Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human Factor VII Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 μl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 μl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Factor VII Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 12 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data

 The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	indard Point ng/ml		Average OD
P1	45	2.130 2.036	2.083
P2	22.5	1.681 1.633	1.657
P3	11.25	1.111 1.179	1.145
P4	5.625	0.685 0.735	0.710
P5	2.813	0.374 0.400	0.387
P6	1.406	0.216 0.204	0.210
P7	0.703	0.116 0.124	0.120
P8	0.0	0.019 0.021	0.020
Sample: Poo Sodium Citrate		0.439 0.461	0.450
Sample: Poo Serum		0.465 0.439	0.452

Standard Curve

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Reference Value

 Plasma and serum samples from healthy adults were tested (n=20). On average, human factor VII level was 536 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	532
Pooled Normal Serum	10	539

Performance Characteristics

- Kit standard has been calibrated against WHO International Standard.
- This assay recognizes factor VII and factor VIIa.
- The minimum detectable dose of human factor VII as calculated by 2SD from the mean of a zero standard was established to be 0.12 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra	-Assay Pred	ision	Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	2.3%	3.3%	3.7%	9.6%	10.4%	11.2%
Average CV (%)	3.1%				10.4%	_

Spiking Recovery

 Recovery was determined by spiking one plasma and one serum sample with different factor VII concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
		4.955	7.855	8.500	108%
Plasma	2.900	2.540	5.440	5.906	109%
		1.228	4.128	4.369	106%
	Serum 2.753	4.955	7.708	8.142	106%
Serum		2.540	5.293	5.491	104%
		1.228	3.981	4.236	106%
	107%				

Linearity

Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)						
Sample Dilution	Plasma	Serum				
80x	90%	103%				
160x	107%	100%				
320x	102%	97%				

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Equine	None
Monkey	20%
Mouse	None
Rat	None
Swine	None
Rabbit	None

 No significant cross-reactivity observed with human factor I (fibrinogen), factor II (prothrombin), factor III (tissue factor), factor V, factor VIII, factor IX, factor X, factor XI, factor XIII, factor XIII, factor XIV (protein C), and VWF proteins.

Troubleshooting

Issue	Causes	Course of Action
	Use of improper components	Check the expiration date listed before use. Do not interchange components from different lots.
Improper wash step		 Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
cisioı	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Low Precision	Inconsistent volumes loaded into wells	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
7	Insufficient mixing of reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
	Improperly sealed microplate	Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.

Microplate was left unattended between	 Each step of the procedure should be performed uninterrupted.
steps	·
Omission of step	Consult the provided procedure for complete list of steps.
Steps performed in	Consult the provided procedure for the correct order.
incorrect order	
	 Check pipette calibration.
reagents added to wells	 Check pipette for proper performance.
Wash step was skipped	 Consult the provided procedure for all wash steps.
Improper wash buffer	 Check that the correct wash buffer is being used.
Improper reagent	 Consult reagent preparation section for the correct
preparation	dilutions of all reagents.
	 Consult the provided procedure for correct incubation
	time.
periods	
	Sandwich ELISA: If samples generate OD values higher than the highest standard a sint (D1) dilute assembles.
	than the highest standard point (P1), dilute samples further and repeat the assay.
Non-ontimal sample	Competitive ELISA: If samples generate OD values lower
	than the highest standard point (P1), dilute samples
unution	further and repeat the assay.
	User should determine the optimal dilution factor for
	samples.
	A new tip must be used for each addition of different
	samples or reagents during the assay procedure.
	Verify that the sealing film is firmly in place before placing
evaporate	the assay in the incubator or at room temperature.
	Pipette properly in a controlled and careful manner. Clearly in attacked as liberation.
improper pipetting	Check pipette calibration. Check pipette for proper performance.
	Check pipette for proper performance. Thereusely a gistate the learning of the property
Insufficient mixing of	 Thoroughly agitate the lyophilized components after reconstitution.
reagent dilutions	Thoroughly mix dilutions.
	steps Omission of step Steps performed in incorrect order Insufficient amount of reagents added to wells Wash step was skipped Improper wash buffer Improper reagent preparation Insufficient or prolonged incubation periods Non-optimal sample dilution Contamination of reagents Contents of wells evaporate Improper pipetting

References

- (1) Davie EW et al. (1979) Adv Enzyme. 48:277.
- (2) Bajaj SP et al. (1981) J Biol Chem. 256:253.
- (3) Kisiel W et al. (1975) Biochemistry. 14:4928.
- (4) Arbini AA et al. (1997) Blood. 89:176.
- (5) Junker R et al. (1997) Arterioscler Thromb Vasc Biol. 17:1539.

Version 4.1-7